Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2020

View Archived Issues

Bayer presents data from the phase II FOXTROT study of osocimab

First-in-human data for NEO-201 in chemoresistant solid tumors

NHP model of Ebola virus infection via mucosal challenge

CureVac and CEPI collaborate to develop vaccine against coronavirus nCoV-2019

Follicum receives grant to study binding of FOL peptides to pancreatic cell receptors

Promising results presented for leronlimab in patients with breast cancer

Vaccitech presents data from the FLU009 phase II study of its VTP-100 vaccine

Adapting NGS for coronavirus surveillance

Long QT genes mostly short on evidence

Immunotherapy combination shows promise in NSCLC

Preclinical data lead to clinical study of in derazantinib in advanced gastric cancer

Exelixis presents phase Ib data for XL-888 plus pembrolizumab in advanced gastrointestinal cancer

Voronoi patents new protein kinase inhibitors

GlaxoSmithKline discloses CREB2 inhibitors

Gilead Sciences describes new IRAK-4 inhibitors

Rodin Therapeutics divulges HDAC inhibitors

Eli Lilly and Company presents SERD inducers for cancer

DB-020 prevents cisplatin-induced hearing loss in animal model, enters clinical trial

Calibr begins first-in-human study of CCW-702 in metastatic castration-resistant prostate cancer

Eisai initiates phase II study of E-7090 in advanced cholangiocarcinoma with FGFR2 gene fusion

Researchers develop an animal model of Marburg virus infection

Gilead provides remdesivir for use in response to novel coronavirus

FDA approves Palforzia oral immunotherapy for peanut allergy

Corvus offers new data from ongoing phase I/Ib trial of CPI-818 in advanced T-cell lymphomas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...